Strides Pharma Science
865.60
-34.05(-3.78%)
Market Cap₹8,291.40 Cr
PE Ratio22.70
IndustryHealthcare
Company Performance:
1D-3.78%
1M+9.22%
6M+22.90%
1Y+109.30%
5Y+382.39%
View Company Insightsright
Latest news about Strides Pharma Science
Strides Pharma Science Reports Strong Q4 Results with US Business Outperforming May 22, 2025
Strides Pharma Science announced impressive Q4 results, with US business revenue reaching $291 million, a 21.80% year-over-year increase. Q4 EBITDA rose 6.37% to 2.17 billion rupees. Overall revenue grew 7.89% to 1160.20 crore Rs, while net profit surged 66.36% to 90.00 crore Rs. The company's EPS increased by 76.06% to 9.56 Rs. Despite strong performance, Strides cautioned about potential inconsistencies in growth markets over the next two years.
Strides Pharma Science Ltd: Q4 Profit Soars, Outperforms Guidance May 22, 2025
Strides Pharma Bolsters Anti-Inflammatory Portfolio with FDA Approval for Celecoxib Capsules Apr 30, 2025
Strides Pharma Expands US Portfolio with $2.075 Million ANDA Acquisition Apr 29, 2025
Strides Pharma Recalls 4.4 Lakh Cartons of Testosterone Gel in US Market Apr 07, 2025
More news about Strides Pharma Science
04Apr 25
Strides Pharma Recalls Over 440,000 Cartons of Testosterone Gel in US Market
Strides Pharma, Inc. has initiated a Class II recall of more than 440,000 cartons of Testosterone Gel in the United States due to benzene contamination. The recall affects two products: 195,952 cartons of 1% Testosterone Gel, 2.5 grams, and 244,412 cartons of 1% Testosterone Gel, 5 grams. The recall was initiated on March 5th in response to the detection of benzene, a known carcinogen not intended to be in the product. This situation may have implications for Strides Pharma's market position in the US and could lead to increased scrutiny of their manufacturing processes.
19Mar 25
Strides Pharma Science Unveils Strategic De-Merger Plan for Arco Lab's Life Sciences and Digital Innovation Business
Strides Pharma Science Limited's Board has approved the de-merger of its subsidiary Arco Lab's Life Sciences and Digital Innovation Capabilities into a new company (NewCo). The NewCo will be a wholly-owned subsidiary of Strides, focusing on Life Sciences and Manufacturing solutions. This restructuring aims to create a specialized entity without financial impact on Strides. Arco Lab will proceed with incorporating NewCo, drafting the scheme of arrangement, and conducting business valuation.
17Mar 25
Strides Pharma Science Subsidiary Eyes Southeast Asian Expansion with Amexel Acquisition
A subsidiary of Strides Pharma Science Ltd plans to acquire a 100% stake in Amexel Pte. Ltd., a Singapore-based company. This strategic move aims to strengthen Strides' presence in Southeast Asia and create a robust business platform in the region. The acquisition aligns with the growing pharmaceutical market in Southeast Asia, driven by increasing healthcare expenditure, population growth, and rising chronic diseases. While financial details remain undisclosed, this acquisition marks a significant step in Strides' international growth strategy.
14Mar 25
Strides Pharma Science Expands Footprint in Southeast Asia with Strategic Acquisition
Strides Pharma Science's subsidiary, Strides Pharma Global Pte. Limited, plans to acquire Amexel Pte. Ltd. for USD 10, aiming to strengthen its Southeast Asian presence. The acquisition, set to complete by March 31, 2025, focuses on technology transfer, supply chain enhancement, and market expansion. Amexel will operate on a revenue generation and profit-sharing model, facilitating partnerships and commercialization across the region.
Strides Pharma Science
865.60
-34.05
(-3.78%)
1 Year Returns:+109.30%
Industry Peers
Sun Pharmaceutical
1,667.20
(-0.51%)
Divis Laboratories
6,856.50
(+0.69%)
Cipla
1,515.70
(+0.65%)
Torrent Pharmaceuticals
3,416.70
(+0.25%)
Dr Reddys Laboratories
1,276.80
(-0.51%)
Zydus Life Science
1,002.50
(+1.27%)
Mankind Pharma
2,287.00
(-1.41%)
Lupin
1,960.90
(+1.18%)
Abbott
34,665.00
(-2.82%)
Aurobindo Pharma
1,132.50
(-0.20%)